Do you want to read an article? Please log in or register.
Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence
Immunotherapy
Related content
Immunotherapy
Immunotherapy for brain tumors: understanding early successes and limitations
Expert Rev Neurother.
Lieberman NAP, Vitanza NA, Crane CA
doi: 10.1080/
Melanoma and Skin CancerImmunotherapy
Identification of essential genes for cancer immunotherapy
Nature.
Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP, Day CP, Robbins P, Feldman S, Merlino G, Zhang F, Restifo NP
doi: 10.1038/nature23477.
ImmunotherapyImmunomodulation
Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy
★ 3
Recommended by
Alexander Meisel, Faculty Member
J Immunother Cancer
Rodrigues Mantuano N, Natoli M, Zippelius A, Läubli H
doi: 10.1136/jitc-2020-001222
Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy
Crit Rev Oncol Hematol.
Solinas C, Porcu M, Hlavata Z, De Silva P, Puzzoni M, Willard-Gallo K, Scartozzi M, Saba L
doi: 10.1016/
Immunotherapy
Immunotherapy in Gastrointestinal Cancers
Biomed Res Int.
Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A, Zagonel V, Lonardi S
doi: 10.1155/2017/4346576.
Immunotherapy
Novel immunotherapy strategies for hepatobiliary cancers
Immunotherapy.
DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ
doi: 10.2217/imt-2018-0024.
RECOMMENDED
Immunotherapy
Development of a novel class of interleukin-2 immunotherapies for metastatic cancer
doi: smw.2019.14697.
Immunotherapy
Is autoimmunity the Achilles' heel of cancer immunotherapy?
Nat Med.
June CH, Warshauer JT, Bluestone JA
doi: 10.1038/nm.4321.
Immunotherapy
Recent progress in therapeutic antibodies for cancer immunotherapy
doi: 10.1016/j.cbpa.2018.05.006.